このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Cullinan Therapeutics 将来の成長

Future 基準チェック /26

Cullinan Therapeuticsの収益は年間9.7%で減少すると予測されていますが、年間収益は年間54.3%で増加すると予測されています。EPS は年間増加すると予測されています。自己資本利益率は 3 年後に-24.5% 2.7%なると予測されています。

主要情報

-9.7%

収益成長率

2.7%

EPS成長率

Biotechs 収益成長	24.1%
収益成長率	54.3%
将来の株主資本利益率	-24.5%
アナリストカバレッジ	Good
最終更新日	03 Jun 2024

今後の成長に関する最新情報

Recent updates

Checking Into Cullinan Therapeutics

Jun 09

Companies Like Cullinan Therapeutics (NASDAQ:CGEM) Are In A Position To Invest In Growth

Apr 23

Companies Like Cullinan Oncology (NASDAQ:CGEM) Are In A Position To Invest In Growth

Jun 24

Here's Why We're Not Too Worried About Cullinan Oncology's (NASDAQ:CGEM) Cash Burn Situation

Mar 05

Companies Like Cullinan Oncology (NASDAQ:CGEM) Are In A Position To Invest In Growth

Oct 08

Cullinan Oncology: Hub-And-Spoke Business Model For Drug Development

Jun 30

Cullinan Oncology (CGEM) Presents At 2021 ASCO Annual Virtual Meeting - Slideshow

Jun 05

Cullinan initiated Buy at H.C. Wainwright on pipeline strength

Feb 02

業績と収益の成長予測

NasdaqGS:CGEM - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	29	-192	N/A	-191	8
12/31/2025	12	-189	N/A	-157	9
12/31/2024	2	-165	N/A	-128	8
3/31/2024	N/A	-132	-122	-122	N/A
12/31/2023	N/A	-153	-134	-134	N/A
9/30/2023	N/A	-156	-142	-141	N/A
6/30/2023	N/A	-142	-163	-161	N/A
3/31/2023	N/A	65	-157	-156	N/A
12/31/2022	N/A	111	-128	-127	N/A
9/30/2022	N/A	105	-117	-117	N/A
6/30/2022	N/A	113	-73	-73	N/A
3/31/2022	N/A	-78	-64	-64	N/A
12/31/2021	19	-66	-43	-43	N/A
9/30/2021	19	-61	-38	-38	N/A
6/30/2021	19	-54	-36	-36	N/A
3/31/2021	19	-47	-26	-26	N/A
12/31/2020	N/A	-52	-30	-30	N/A
9/30/2020	N/A	-28	-25	-25	N/A
6/30/2020	N/A	-25	-22	-22	N/A
3/31/2020	N/A	-21	-21	-21	N/A
12/31/2019	N/A	-21	-21	-21	N/A

アナリストによる今後の成長予測

収入対貯蓄率: CGEM今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: CGEM今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: CGEM今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: CGEMの収益 ( 54.3% ) US市場 ( 8.7% ) よりも速いペースで成長すると予測されています。

高い収益成長: CGEMの収益 ( 54.3% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: CGEM 3 年以内に赤字になると予測されています。

Cullinan Therapeutics 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Consensus EPS estimates upgraded to US$3.01 loss

Consensus revenue estimates increase by 19%

Price target increased by 13% to US$28.71

Price target decreased by 11% to US$25.25

Price target decreased to US$34.00

Price target decreased to US$39.25

Recent updates

Independent Director exercised options to buy US$402k worth of stock.

Checking Into Cullinan Therapeutics

Cullinan Therapeutics, Inc. Announces Positive Initial Data from Pivotal Phase 2b Rezil1 Study of Zipalertinib

Independent Director exercised options to buy US$2.4m worth of stock.

Consensus EPS estimates upgraded to US$3.01 loss

Cullinan Therapeutics, Inc., Annual General Meeting, Jun 26, 2024

Cullinan Therapeutics, Inc. Announces Board Changes

Chief Scientific Officer notifies of intention to sell stock

Consensus revenue estimates increase by 19%

Cullinan Therapeutics, Inc Appoints Mary Kay Fenton as Chief Financial Officer

Companies Like Cullinan Therapeutics (NASDAQ:CGEM) Are In A Position To Invest In Growth

Price target increased by 13% to US$28.71

Cullinan Oncology, Inc. announced that it expects to receive $280.000024 million in funding

Cullinan Oncology, Inc. Announces Resignation of Jeff Trigilio as Chief Financial Officer , Effective from March 29, 2024

Cullinan Oncology, Inc. Announces Resignation of Jeff Trigilio as Chief Financial Officer , Effective from March 29, 2024

Chief Business Officer notifies of intention to sell stock

New minor risk - Shareholder dilution

Cullinan Oncology, Inc. Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-617, a Novel Fusion Protein Uniquely Harnessing Both IL-2 and IL-12 Cytokines

Cullinan Oncology, Inc. to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023

Price target decreased by 11% to US$25.25

New minor risk - Profitability

Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Oncology, Inc. Announces the Launch of the REZILIENT3 Trial

Investor sentiment improves as stock rises 17%

High number of new and inexperienced directors

Chief Development Officer notifies of intention to sell stock

Investor sentiment improves as stock rises 16%

Cullinan Oncology, Inc. Announces First Clinical Data from its Phase 1 Study of CLN-619 in Patients with Advanced Solid Tumors

Cullinan Oncology, Inc. Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-978, Novel T-Cell Engager for Treatment of Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Investor sentiment deteriorated over the past week

Chief Development Officer notifies of intention to sell stock

Price target decreased to US$34.00

Cullinan Oncology Appoints of David P. Ryan to Its Board of Directors

Investor sentiment improved over the past week

Cullinan Oncology: Modality-Agnostic Approach To Yield Fruit In Coming Years

Cullinan Oncology: One Of The Leaders In Cancer Treatment Development

Cullinan Oncology grants stock options for 125.7K shares

Cullinan Oncology, Inc. Appoints Jacquelyn Sumer as Chief Legal Officer

Insider recently sold US$712k worth of stock

Chief Business Officer notifies of intention to sell stock

Chief Business Officer notifies of intention to sell stock

Cullinan Oncology, Inc.(NasdaqGS:CGEM) dropped from Russell 2000 Growth Index

Insider recently sold US$1.3m worth of stock

Taiho Pharmaceutical Co., Ltd. completed the acquisition of Cullinan Pearl Corp from Cullinan Oncology, Inc. (NasdaqGS:CGEM).

Companies Like Cullinan Oncology (NASDAQ:CGEM) Are In A Position To Invest In Growth

President recently bought US$100k worth of stock

Insider recently sold US$4.0m worth of stock

Price target decreased to US$39.25

Forecast to breakeven in 2022

Taiho Pharmaceutical Co., Ltd. entered into a Share Purchase Agreement to acquire Cullinan Pearl Corp from Cullinan Oncology, Inc. (NasdaqGS:CGEM) for approximately $400 million.

Cullinan Oncology, Inc., Annual General Meeting, Jun 22, 2022

Cullinan Oncology Announces Clinical and Regulatory Update for CLN-081 in NSCLC EGFR Exon 20 Patients

Cullinan Oncology, Inc. to Present Data Demonstrating Breadth and Progress of Its Immuno-Oncology Portfolio At American Association for Cancer Research 2022

Here's Why We're Not Too Worried About Cullinan Oncology's (NASDAQ:CGEM) Cash Burn Situation

Cullinan Oncology, Inc. Announces Management Appointments

Price target decreased to US$47.75

U.S. Food and Drug Administration Grants Breakthrough Therapy Designation for Cln-081 for the Treatment of Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Strategic Advisor notifies of intention to sell stock

Cullinan Oncology, Inc. Announces Updated Phase 1/2a Data for CLN-081 in NSCLC EGFR Exon 20 Patients

CFO & Treasurer exercised options and sold US$166k worth of stock

Companies Like Cullinan Oncology (NASDAQ:CGEM) Are In A Position To Invest In Growth

Chief Development Officer of Biologics exercised options and sold US$81k worth of stock

CFO & Treasurer exercised options and sold US$363k worth of stock

Insider recently sold US$815k worth of stock

Chief Development Officer of Biologics notifies of intention to sell stock

Insider notifies of intention to sell stock

Insider recently sold US$753k worth of stock

Cullinan Oncology: Hub-And-Spoke Business Model For Drug Development

Cullinan Oncology, Inc. Receives FDA Clearance of Investigational New Drug (IND) Application for CLN-619, a Novel MICA/B-targeted Antibody for the Treatment of Solid Tumors

Cullinan Oncology, Inc. Receives Investigational New Drug Clearance from the FDA for CLN-049, a FLT3 x CD3 Bispecific Antibody for the Treatment of Relapsed/Refractory AML